公开(公告)号：US6132722A

公开(公告)日：2000-10-17

申请号：US070637

申请日：1998-04-30

Applicant: Nathan O. Siemers ,  Susan Yarnold ,  Peter D. Senter

Inventor： Nathan O. Siemers ,  Susan Yarnold ,  Peter D. Senter

IPC: C12N15/09 ,  A61K31/131 ,  A61K31/337 ,  A61K31/407 ,  A61K31/704 ,  A61K38/00 ,  A61K45/06 ,  A61K47/48 ,  A61P35/00 ,  A61P43/00 ,  C07K16/30 ,  C07K19/00 ,  C12N9/78 ,  A61K39/395 ,  A61K47/16 ,  C12N9/96

CPC classification number: B82Y5/00 ,  A61K47/4843 ,  A61K47/48623 ,  A61K47/48723 ,  A61K47/48761 ,  C07K16/3053 ,  A61K2039/505 ,  C07K2319/00 ,  Y10S530/866 ,  Y10S530/867

Abstract: The invention is related to recombinantly produced fusion polypeptides comprising antibody V.sub.H and V.sub.L sequences operatively linked to a .beta.-lactamase for use in the delivery of cytotoxic drugs to tumor cells.

Abstract translation: 本发明涉及重组产生的融合多肽，其包含与β-内酰胺酶有效连接的抗体VH和VL序列，用于向肿瘤细胞递送细胞毒性药物。

公开(公告)号：US6025477A

公开(公告)日：2000-02-15

申请号：US386221

申请日：1995-02-09

Applicant: Emanuel Calenoff

Inventor： Emanuel Calenoff

IPC: A61K38/00 ,  A61K41/00 ,  A61K47/48 ,  C07K14/47 ,  C07K14/78 ,  C07K16/18 ,  C07K16/46 ,  C12N5/18 ,  G01N33/533 ,  G01N33/543 ,  G01N33/544 ,  G01N33/564 ,  G01N33/68 ,  G01N33/92 ,  C07K17/00

CPC classification number: A61K47/48538 ,  A61K47/4843 ,  A61K47/48676 ,  C07K14/47 ,  C07K14/78 ,  C07K16/18 ,  C07K16/468 ,  G01N33/533 ,  G01N33/543 ,  G01N33/544 ,  G01N33/564 ,  G01N33/686 ,  G01N33/92 ,  A61K38/00 ,  G01N2800/323

Abstract: This invention provides purified antigens which are indicative of the presence of atherosclerotic plaque. Different concentrations of these antigens have been found to coincide with the progression of atherosclerosis. The subject invention also provides different hybridoma cell lines which produce monoclonal antibodies directed to antigens associated with atherosclerosis and a hybridoma cell line which produces monoclonal antibodies directed to antigen associated with normal artery and not with plaque. The atherosclerotic plaque antigen, and monoclonal antibodies made thereto, are used in various methods for detecting in a biological sample an antigen present in, and indicative of the presence of, atherosclerotic plaque. The monoclonal antibodies are also used in methods of imaging atherosclerotic plaque, and treating atherosclerosis. The methods of treating atherosclerosis include a method of digesting atherosclerotic plaque with enzymes, and a method of ablating atherosclerotic plaque using radiation. The subject invention also provides a method of treating atherosclerotic plaque by directly delivering a drug to the plaque. The subject invention further provides a method for treating atherosclerosis by blocking the synthesis of atherosclerotic plaque or by blocking binding of antibodies to the antigen.

Abstract translation: 本发明提供了指示存在动脉粥样硬化斑块的纯化抗原。 已经发现不同浓度的这些抗原与动脉粥样硬化的进展相一致。 本发明还提供了不同的杂交瘤细胞系，其产生针对与动脉粥样硬化相关的抗原的单克隆抗体和产生针对与正常动脉相关的抗原而不与斑块相关的抗原的单克隆抗体的杂交瘤细胞系。 动物动脉粥样硬化斑块抗原及其制备的单克隆抗体用于各种方法用于在生物样品中检测存在于动脉粥样硬化斑块中并存在动脉粥样硬化斑块的抗原。 单克隆抗体也用于成像动脉粥样硬化斑块和治疗动脉粥样硬化的方法。 治疗动脉粥样硬化的方法包括用酶消化动脉粥样硬化斑块的方法，以及使用辐射消融动脉粥样硬化斑块的方法。 本发明还提供了通过将药物直接递送至斑块来治疗动脉粥样硬化斑块的方法。 本发明还提供了通过阻断动脉粥样硬化斑块的合成或通过阻断抗体与抗原的结合来治疗动脉粥样硬化的方法。

公开(公告)号：US5210076A

公开(公告)日：1993-05-11

申请号：US609311

申请日：1990-11-05

Applicant: David L. Berliner ,  Robert L. Erwin ,  David R. McGee

Inventor： David L. Berliner ,  Robert L. Erwin ,  David R. McGee

IPC: A61K31/53 ,  A61K9/12 ,  A61K31/40 ,  A61K31/41 ,  A61K31/69 ,  A61K31/70 ,  A61K31/711 ,  A61K31/787 ,  A61K31/795 ,  A61K33/20 ,  A61K38/00 ,  A61K38/22 ,  A61K38/43 ,  A61K38/44 ,  A61K39/395 ,  A61K45/00 ,  A61K47/48 ,  A61K48/00 ,  A61K51/00 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61P27/02 ,  A61P43/00 ,  C12N9/02 ,  C12P17/00 ,  C12P17/18 ,  C12R1/465

CPC classification number: C12P17/00 ,  A61K31/40 ,  A61K31/69 ,  A61K33/22 ,  A61K38/185 ,  A61K38/22 ,  A61K47/48415 ,  A61K47/4843 ,  A61K48/00 ,  C12N9/0059 ,  C12N9/0071 ,  C12Y110/03001 ,  C12Y114/18001 ,  A61K38/00

Abstract: The invention is directed to the treatment of degenerative diseases of tissues which have lost melanin and which share a common embryological basis as tissues of the nervous system by the administration of an active substance which causes an increased concentration of melanin in the tissue. Such active substances include melanin, melanin variants, melanin analogs, melanin derivatives, tyrosinase, tyrosinase gene, melanin-concentrating hormone and combinations thereof. Examples. of such diseases include Parkinson's disease, Alzheimer's disease, retinitis pigmentosa, schizophrenia and dementia. The invention is also useful in assisting in the repair of neurons in a mammal having neuron damage by administering an effective amount of an active substance which causes an increased concentration of melanin in the neuron to aid in nerve repair. The invention is further useful in protecting a mammal from a toxin-induced disease or from the adverse effects of a toxin by administering an effective amount of the active substance described above.

Abstract translation: 本发明涉及通过施用导致组织中黑色素浓度增加的活性物质而失去黑色素的组织的退行性疾病的治疗，其通过神经系统的组织共享共同的胚胎学基础。 这些活性物质包括黑色素，黑色素变体，黑色素类似物，黑色素衍生物，酪氨酸酶，酪氨酸酶基因，黑色素浓缩激素及其组合。 例子。 的疾病包括帕金森病，阿尔茨海默病，色素性视网膜炎，精神分裂症和痴呆。 本发明还可用于通过施用有效量的活性物质来辅助具有神经元损伤的哺乳动物的神经元的修复，所述活性物质引起神经元中黑色素浓度增加以帮助神经修复。 本发明还可用于通过施用有效量的上述活性物质来保护哺乳动物免受毒素诱发的疾病或毒素的不利影响。

公开(公告)号：US5120834A

公开(公告)日：1992-06-09

申请号：US364053

申请日：1989-06-08

Applicant: Paul E. Gargan ,  Victoria A. Ploplis ,  Julian R. Pleasants

Inventor： Paul E. Gargan ,  Victoria A. Ploplis ,  Julian R. Pleasants

IPC: A23K1/16 ,  A61K38/00 ,  A61K38/43 ,  A61K39/395 ,  A61K45/00 ,  A61K47/48 ,  A61K49/00 ,  A61P7/02 ,  A61P35/00 ,  C07K14/76 ,  C07K16/00 ,  C07K16/18 ,  C07K16/36 ,  C07K19/00 ,  C12N5/10 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/531 ,  G01N33/573 ,  G01N33/577 ,  G01N33/86

CPC classification number: G01N33/86 ,  A61K39/39533 ,  A61K47/4843 ,  C07K16/18 ,  C07K16/36 ,  G01N33/531 ,  G01N33/573 ,  A61K38/00 ,  G01N2333/745 ,  G01N2333/75 ,  G01N2333/972 ,  G01N2333/9723

Abstract: The subject invention relates to a fibrin-specific monoclonal antibody wherein said monoclonal antibody does not crossreact with: (a) fibrinogen, (b) plasmin derived fibrinogen degradation products and (c) plasmin derived fibrin degradation products.

Abstract translation: 本发明涉及一种纤维蛋白特异性单克隆抗体，其中所述单克隆抗体不与以下物质相交反应：（a）纤维蛋白原，（b）纤溶酶衍生的纤维蛋白原降解产物和（c）纤溶酶衍生的纤维蛋白降解产物。

公开(公告)号：US20170088619A1

公开(公告)日：2017-03-30

申请号：US15378972

申请日：2016-12-14

Applicant: Immunomedics, Inc.

Inventor： Chien-Hsing Chang ,  David M. Goldenberg

IPC: C07K16/28 ,  C12N15/113 ,  C07K16/30 ,  C07K16/18 ,  C07K16/44

CPC classification number: C07K16/2833 ,  A61K31/4965 ,  A61K47/484 ,  A61K47/48423 ,  A61K47/4843 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6815 ,  A61K47/6849 ,  A61K47/6881 ,  A61K47/6885 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2851 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/77 ,  C07K2319/70 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/3513 ,  C12N2320/32 ,  Y02A50/403

Abstract: Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.

公开(公告)号：US5492821A

公开(公告)日：1996-02-20

申请号：US791915

申请日：1991-11-13

Applicant: Matthew R. Callstrom ,  Mark D. Bednarski ,  Patrick R. Gruber

Inventor： Matthew R. Callstrom ,  Mark D. Bednarski ,  Patrick R. Gruber

IPC: A61K47/48 ,  C07H5/06 ,  C07H13/04 ,  C07H15/12 ,  C07K16/12 ,  C07K16/44 ,  C08F8/30 ,  C08F8/34 ,  C12N11/06 ,  C12N11/08 ,  G01N33/545 ,  G01N33/58 ,  C12N9/00 ,  C12N9/96

CPC classification number: C07H5/06 ,  A61K47/48176 ,  A61K47/4843 ,  A61K47/48692 ,  C07H13/04 ,  C07H15/12 ,  C07K16/1292 ,  C07K16/44 ,  C08F8/30 ,  C08F8/34 ,  C12N11/06 ,  C12N11/08 ,  G01N33/545 ,  G01N33/581 ,  Y10S530/816

Abstract: This invention is directed to water soluble protein polymer conjugates which are stabile in hostile environments. The conjugate comprises a protein which is linked to an acrylic polymer at multiple points through saccharide linker groups.

Abstract translation: 本发明涉及在恶劣环境中稳定的水溶性蛋白质聚合物缀合物。 缀合物包含通过糖连接基团在多个点与丙烯酸聚合物连接的蛋白质。

公开(公告)号：US5490988A

公开(公告)日：1996-02-13

申请号：US335925

申请日：1994-11-08

Applicant: Thomas S. Beggs ,  Paul J. Davis ,  Martine E. Verhoeyen

Inventor： Thomas S. Beggs ,  Paul J. Davis ,  Martine E. Verhoeyen

IPC: A61K9/06 ,  A61K8/66 ,  A61K9/08 ,  A61K9/20 ,  A61K38/44 ,  A61K39/395 ,  A61K47/48 ,  A61P1/02 ,  A61Q11/00 ,  C07K16/42 ,  A61K7/16 ,  A61K39/00

CPC classification number: A61K47/4843 ,  A61K47/487 ,  A61K8/66 ,  A61Q11/00 ,  C07K16/4283 ,  A61K2800/94

Abstract: An antibody fragment able to bind to a target site is prolonged by an additional peptide. The Therapeutic agent is bound to this peptide or means are provided to bring about such binding. The antibody fragment and possibly also the therapeutic agent are included in a product so that binding to the target site delivers the therapeutic agent to the vicinity. The product may for example be for dental care, such as a toothpaste or mouthwash and the antibody fragment may then bind to a component of dental plaque.

Abstract translation: 能够结合靶位点的抗体片段被另外的肽延长。 治疗剂与该肽结合或提供手段以产生这种结合。 抗体片段和可能的治疗剂包括在产品中，使得与靶位点的结合将治疗剂递送到附近。 该产品可以例如用于牙科保健，例如牙膏或漱口剂，并且抗体片段然后可以结合牙菌斑的组分。

公开(公告)号：US5336493A

公开(公告)日：1994-08-09

申请号：US836274

申请日：1992-03-02

Applicant: Mark J. Poznansky ,  Guo D. Mao

Inventor： Mark J. Poznansky ,  Guo D. Mao

IPC: A61K38/44 ,  A61K47/48 ,  C12N9/96 ,  A61K37/62 ,  A61K37/50 ,  C12N9/08

CPC classification number: A61K38/44 ,  A61K38/446 ,  A61K47/4843 ,  C12N9/96 ,  C12Y111/01006 ,  C12Y115/01001

Abstract: Novel multi-component conjugates are provided having at least two components which are superoxide dismutase and catalase. Novel therapeutic agents utilising these conjugates are provided which are effective to reduce harmful levels of superoxide and hydroxyl free radicals in body tissues.

Abstract translation: PCT No.PCT / CA90 / 00279 Sec。 371日期：1992年3月2日 102（e）1992年3月2日PCT PCT 1990年8月30日PCT公布。 出版物WO91 / 03548 日期1991年3月21日。提供具有至少两种成分的新型多组分共轭物，其为超氧化物歧化酶和过氧化氢酶。 提供了利用这些缀合物的新型治疗剂，其有效降低身体组织中超氧化物和羟基自由基的有害水平。

公开(公告)号：US5256413A

公开(公告)日：1993-10-26

申请号：US946015

申请日：1992-09-15

Applicant: Edgar Haber ,  Gary R. Matsueda

Inventor： Edgar Haber ,  Gary R. Matsueda

IPC: A61K47/48 ,  A61K39/395 ,  C07K15/28

CPC classification number: A61K47/4843

Abstract: Disclosed is a method for the in vivo lysis of a thrombus in a host by administration of a conjugate consisting of a monoclonal antibody specific for fibrin coupled to a plasminogen activator such as tissue plasminogen activator, urokinase or streptokinase.

Abstract translation: 公开了一种通过施用由对纤维蛋白特异性的纤维蛋白特异性的单克隆抗体组合的缀合物体内裂解宿主中的血栓的方法，所述结合纤维蛋白偶联于纤溶酶原激活剂如组织纤溶酶原激活剂，尿激酶或链激酶。

公开(公告)号：US4673573A

公开(公告)日：1987-06-16

申请号：US689846

申请日：1985-01-09

Applicant: Harry Ferres ,  Richard A. G. Smith ,  Andrew J. Garman

Inventor： Harry Ferres ,  Richard A. G. Smith ,  Andrew J. Garman

IPC: C07D213/70 ,  A61K38/00 ,  A61K38/16 ,  A61K38/46 ,  A61K38/48 ,  A61K39/395 ,  A61K47/48 ,  A61P7/02 ,  A61P43/00 ,  C12N9/64 ,  C12N9/72 ,  C12N11/02 ,  C12Q1/56 ,  C12N9/48 ,  C12N9/68 ,  C12N9/96

CPC classification number: C12N9/6456 ,  A61K47/4843 ,  C12N11/02 ,  A61K38/00 ,  Y10S530/812

Abstract: A fibrinolytically active protein conjugate comprising at least one optionally blocked fibrinolytic enzyme linked by way of a site other than the catalytic site responsible for fibrinolytic activity to at least one human protein.Processes from making the conjugates and pharmaceutical compositions containing them are also described.

Abstract translation: 包含至少一种任选阻断的纤维蛋白溶解酶的纤维蛋白溶解活性蛋白质缀合物，其通过除负责纤维蛋白溶解活性的催化位点之外的位点与至少一种人蛋白质相连。 还描述了制备共轭物和含有它们的药物组合物的方法。